Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0C2OR
|
||||
| Former ID |
DIB011124
|
||||
| Drug Name |
MIM-D3
|
||||
| Synonyms |
TrkA agonist (ocular disease/Alzheimer's disease), Mimetogen
|
||||
| Indication | Alzheimer disease [ICD9: 331; ICD10:G30] | Phase 3 | [1] | ||
| Company |
Mimetogen Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
c12c(ccc(c1)[N+](=O)[O-])OCC[C@H](NC(=O)[C@@H](NC(=O)[C<br />@@H](NC2=O)CCC(=O)O)CCCCN)C(=O)NCC(=O)O
|
||||
| Target and Pathway | |||||
| Target(s) | Neurotrophic tyrosine kinase receptor 1 | Target Info | Agonist | [2] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Endocytosis | |||||
| Apoptosis | |||||
| Neurotrophin signaling pathway | |||||
| Inflammatory mediator regulation of TRP channels | |||||
| Pathways in cancer | |||||
| Transcriptional misregulation in cancer | |||||
| Thyroid cancer | |||||
| Central carbon metabolism in cancer | |||||
| NetPath Pathway | IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Neurotrophic factor-mediated Trk receptor signaling | ||||
| Reactome | Frs2-mediated activation | ||||
| ARMS-mediated activation | |||||
| NGF-independant TRKA activation | |||||
| PI3K/AKT activation | |||||
| WikiPathways | MAPK Signaling Pathway | ||||
| BDNF signaling pathway | |||||
| Integrated Pancreatic Cancer Pathway | |||||
| NGF signalling via TRKA from the plasma membrane | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01960010) A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye. U.S. National Institutes of Health. | ||||
| REF 2 | Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye. Clin Ophthalmol. 2013; 7: 1275-1285. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.